期刊文献+

替米沙坦对伴有糖尿病及高血压的冠心病患者治疗前后血浆炎症因子的变化及心功能的影响 被引量:8

下载PDF
导出
摘要 目的探讨替米沙坦作为过氧化物酶体增殖物活化受体γ(PPARγ)激动剂对伴有糖尿病及高血压的冠心病患者血浆炎症因子水平的影响。方法将240例伴有糖尿病及高血压的冠心病患者随机分为口服替米沙坦组(n=120)和雷米普利组(n=120),随访12个月,用酶联免疫吸附法测定患者在治疗前和治疗后12个月的血浆C-反应蛋白、肿瘤坏死因子-α(TNF-α)水平,并观察血糖、胰岛素水平、胰岛素抵抗指数及血脂水平的改变。结果替米沙坦组患者用替米沙坦治疗12个月后,C-反应蛋白及TNF-α显著下降(P<0.01),空腹血糖、血清胰岛素及胰岛素抵抗指数亦明显降低(P<0.05),相关分析提示,C-反应蛋白、TNF-α的降低幅度与血糖水平呈负相关(r=-0.41和r=-0.45,P<0.01);雷米普利组患者用雷米普利治疗12个月后,C-反应蛋白及TNF-α明显降低(P<0.05),其他指标无明显的变化。替米沙坦组患者用替米沙坦治疗12个月后,心血管事件发生率显著下降(P<0.01)。结论替米沙坦在提高胰岛素的敏感性、改善糖代谢的同时,能够降低伴有糖尿病及高血压的冠心病患者血浆C-反应蛋白、TNF-α水平以及显著改善左室功能。
出处 《广东医学》 CAS CSCD 北大核心 2008年第12期2098-2100,共3页 Guangdong Medical Journal
  • 相关文献

参考文献9

  • 1LEBOVITZ H, DDE J F, PATWARDHAN R, et al. Rosiglitazone monotherapy is effective in patients with type 2diabetes[ J]. J Clin Endocfinol Metab, 2001, 86 : 280 - 288.
  • 2毛节明.过氧化物酶体增殖物活化受体——开启冠心病防治之门的新钥匙[J].中国循环杂志,2004,19(4):243-244. 被引量:2
  • 3MATTEWS D R, HOSKER J P, RUDENSKi A S, et al. Homeostasis model assessment : Insulin resistance and beta - cell function from fasting plasma glucose and insulin concentration in man [ J ]. Diabetologia, 1985, 28 : 412 -419.
  • 4李曦铭,王林.炎性细胞因子在心力衰竭中的研究进展[J].天津医药,2004,32(6):382-384. 被引量:5
  • 5YAMAGISHI S, TAKEUCHI M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR -gamma- inducing property[J]. Med Hypotheses, 2005, 64 ( 3 ) :476 - 478.
  • 6KURTZ T W, PRAVENEC M. Antidiabetic mechanisms of angiotensin - converting enzyme inhibitors and angiotensin Ⅱ receptor antagonists : beyond the renin - angiotensin system [ J ]. J Hypertens, 2004, 22(12) : 2 253 -2 261.
  • 7DOGGRELL S A. Telmisartan - killing two birds with one stone [J]. Expert Opin Pharmacother, 2004, 5( 11 ): 2 397-2 400.
  • 8DE GASPARO M, LEVENS N. Does blockade of angiotensin Ⅱreceptors offer clinical benefits over inhibition of angiotensin - converting enzyme? [J]. Pharmacol Toxicol, 1998, 82:257-271.
  • 9STRUTHERS A D. Aldosterone escape during angiolensin - converting enzyme inhibitor therapy in chronic heart failure[J]. J Card Fail, 1996, 2:47 -54.

二级参考文献27

  • 1Kapadia S, Dibbs Z, Kurrelmeyer K, et al.The role of cytokines in the failing human heart. In: Crawford M, ed .Cardiology Clinics. Philadephia, Pa : WB Saunders, 1998. 645 -652.
  • 2Mann DL. Cytokines as mediators of disease progression in the failing heart. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. Philadelphia, Pa: Lippincott Williams and Wilkins, 1999. 213 - 221.
  • 3Kumar A, Brar R, Wang P, et al. Role of nitric oxide and cGMP in human septic serum - induced depression of cardiac myocyte contractility. Am J Physiol, 1999, 276:R265 - R276.
  • 4Alastair Gracie J. Interleukin- 18.J Leu Biol, 2003, 73: 213-226.
  • 5Pomerantz BJ, Reznikov LL. Inhibition of caspase- 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL- 1β. Proc Natl Acad Sci USA, 2001,98: 2871- 2885.
  • 6Pagani FD, Baker LS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosi factor - α in conscious dogs. J Clin Invest, 1992, 90 : 389 - 398.
  • 7Kubota T, McTiernan CF. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpressio of tmor necrosis factor -α . Circ Res, 1997, 81 : 627 - 635.
  • 8Knittel T, Mehde M, Grundmann A, et al. Expression of matrix rnetalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol, 2000, 113:443- 453.
  • 9Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1999, 83:376 382.
  • 10Deswal A, Petersen N J, Fedldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarione Trial(VEST) . Circulation, 2001, 103 : 2055 - 2059.

共引文献5

同被引文献72

引证文献8

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部